Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Antipsychotic or D2/D3/5HT1A partial agonist or Sedative-hypnotic

Use the filters below to narrow your results.

generic:
brand:
None (9)
classes: (Click arrow to add another value)
mechanism:
None (3) · Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Extremely potent GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator (15) · GABAA positive allosteric modulator (non-benzodiazepine) (3) · GABAA positive allosteric modulator; very long half-life (1) · GABAA potentiator (1) · GABAA potentiator and direct activator (2) · GABAB agonist; GHB receptor agonist (1) · Melatonin receptor agonist (2) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Multi-receptor antagonist; low D2 affinity (1) · Phenothiazine D2 antagonist (5) · Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) · Selective GABAA agonist (extrasynaptic delta subunit) (1) · Thioxanthene D2 antagonist (1)
uses:
None (46) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1)
starting dose:
None (46) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)
preparations:
None (46) · 1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
fda max:
None (46) · 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) (1) · N/A (never approved) (1)
routes:
None (46) · intranasal; rectal and IV reported. (1) · Oral (2) · sublingual (1)
onset:
None (46) · Weeks for psychosis/mood efficacy (1) · ~20–40 min PO; faster sublingual/intranasal. (1)
duration:
None (46) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1)
halflife:
None (46) · Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1)
bioavailability:
None (46) · Adequate oral bioavailability (1) · Not formally characterized in humans. (1)
pregnancy:
None (46) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Limited data (1)
legal:
None (47) · Rx (1)

Showing below up to 48 results in range #1 to #48.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"